Fighting the Hidden Battle: Protecting Ovarian Cancer Patients with Advanced Diagnostics
When we talk about ovarian cancer, the conversation typically centers around early detection, genetic predisposition, and treatment options like surgery or chemotherapy. But there’s another critical aspect that often goes unnoticed—the silent threat of infections in immunocompromised patients.
Why Infections Are a Serious Concern in Ovarian Cancer
Ovarian cancer patients often undergo aggressive treatments, including chemotherapy and radiation therapy. While these are essential to combat the cancer itself, they severely weaken the immune system, leaving patients vulnerable to opportunistic infections. These infections are not just a minor side effect—they can be life-threatening, especially when they are not diagnosed and treated in time.
According to a study published in the Journal of Clinical Oncology, nearly 30% of cancer patients hospitalized with febrile neutropenia succumb within 30 days.
